Drug screening market seen reaching $19.2 billion by 2030

The drug screening market is projected to climb from $11.18 billion in 2026 to $19.2 billion by 2030 as workplace testing, clinical trials, and regulatory compliance drive demand. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Drug screening is becoming more important as employers, labs, regulators, and law enforcement expand testing for substance use. - The market’s growth points to broader adoption of rapid tests, digital reporting, and portable devices across healthcare and compliance settings.

What happened: - The Business Research Company projected the global drug screening market at $11.18 billion in 2026, up from $9.72 billion in 2025. - The report forecast the market will reach $19.2 billion by 2030, with a 14.5% compound annual growth rate. - The report covers market size, trends, and forecasts for 2026-2035. - The company also offered a free sample report and the full market report.

The details: - The 2026 growth forecast reflects wider workplace drug testing, more clinical trial activity, stricter law enforcement screening, growth in diagnostic labs, and wider access to rapid test kits. - The report said future growth will also be supported by AI-enabled screening analytics, portable drug testing devices, compliance testing, real-time reporting, and multi-panel screening. - Drug screening uses biological samples such as blood, urine, hair, or saliva to detect drugs or metabolites. - The approach is used in clinical trials and other diagnostic settings to identify chemicals, pollutants, and illicit substances in the body. - The report highlighted rising use of rapid testing kits, automated laboratory screening, digital reporting integration, point-of-care testing, and better detection accuracy as key trends. - The report identified North America as the largest regional market in 2025. - The Asia-Pacific region is expected to grow fastest over the forecast period. - The report also reviewed South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - Rising global drug use is a major demand driver for screening services. - The report cited United Nations Office on Drugs and Crime data showing 316 million people ages 15 to 64 used drugs in 2023, excluding alcohol and tobacco. - Cannabis was the most used drug at 244 million users, followed by opioids at 61 million, amphetamines at 30.7 million, cocaine at 25 million, and ecstasy at 21 million. - The data suggests demand is being pushed by both public health concerns and stricter compliance needs.

What's next: - The market is expected to keep expanding as testing moves toward faster, more automated, and more portable formats. - Technology upgrades in AI analytics and digital reporting are likely to shape competition and product development. - Regional growth may increasingly shift toward Asia-Pacific as adoption broadens beyond North America.

The bottom line: - Drug screening is moving from a niche compliance tool to a broader diagnostics and monitoring market with strong double-digit growth through 2030.